Elevated activity of the mitogen-activated protein kinase (MAPK) signaling cascade is found in the majority of human melanomas and is known to regulate proliferation, survival and invasion. Current targeted therapies focus on decreasing the activity of this pathway; however, we do not fully understand how these therapies impact tumor biology, especially given that melanoma is a heterogeneous disease. Using a three-dimensional (3D), collagen-embedded spheroid melanoma model, we observed that MEK and BRAF inhibitors can increase the invasive potential of B20% of human melanoma cell lines. The invasive cell lines displayed increased receptor tyrosine kinase (RTK) activity and activation of the Src/FAK/signal transducers and activators of transcription-3 (STAT3) signaling axis, also associated with increased cell-to-cell adhesion and cadherin engagement following MEK inhibition. Targeting various RTKs, Src, FAK and STAT3 with small molecule inhibitors in combination with a MEK inhibitor prevented the invasive phenotype, but only STAT3 inhibition caused cell death in the 3D context. We further show that STAT3 signaling is induced in BRAF-inhibitor-resistant cells. Our findings suggest that MEK and BRAF inhibitors can induce STAT3 signaling, causing potential adverse effects such as increased invasion. We also provide the rationale for the combined targeting of the MAPK pathway along with inhibitors of RTKs, SRC or STAT3 to counteract STAT3-mediated resistance phenotypes.
INTRODUCTION
Melanoma arises from the transformation of melanocytes that have accumulated mutations in growth-regulating genes and display increased levels of autocrine/paracrine growth factors; this eventually leads to their uncontrolled proliferation, survival and dissemination. 1 Contributing to this transformation, the mitogenactivated protein kinase (MAPK) pathway becomes constitutively activated in the majority of melanomas, most notably in tumors harboring activating RAS and RAF mutations. 2 Targeting the MAPK pathway thus became a valid anti-melanoma therapeutic strategy, and current trials using RAF-selective inhibitors for patients with BRAFV600E-positive tumors are proof of the potential to treat tumors, even advanced metastatic disease. [3] [4] [5] [6] Therapeutic challenges arise, however, in the form of acquired resistance in initially responsive patients, or through intrinsic resistance as shown by tumors that do not respond or even adopt more aggressive phenotypes. 5, 7, 8 Mechanisms conferring resistance to RAF inhibitors are numerous but the MAPK pathway frequently becomes reactivated despite the continued presence of inhibitors designed to block its activity. [9] [10] [11] [12] [13] In addition, other pathways and effectors appear to become engaged such as the PI3K/Akt pathway and receptor tyrosine kinases (RTKs) such as IGFR, platelet-derived growth factor receptor beta (PDGFRb) or the HGF receptor. 9, [14] [15] [16] Secondary genetic modifications were also shown to occur, such as amplifications of COT, mutations such as MEK1 (C121S), as well as RAS mutations. 14, 17, 18 Unlike RAF-selective inhibitors, MEK inhibitors downregulate MEK and ERK activity in most cells, irrespective of RAF mutation status, and can be used for a wider patient population. 19, 20 However, MEK inhibitor clinical success as single agents has often been limited by toxicity, and the response rate for mutant-BRAF melanoma was shown to be lower than that for RAF inhibitors (reviewed in Nissan and Solit 21 ). Their use is also challenged by the fact that MEK inhibitor response does not always correlate with mutation or phospho-protein markers associated with BRAF, MEK, RAS or PI3K activity, suggesting the need to rely on transcriptional pathway signatures or discover new predictive targets. 20 The development of novel and more potent MEK inhibitors, such as trametinib, could allow MEK to resurface as an exciting clinical target, especially for mutant-BRAF melanomas where improved survival was recently observed; 22 however, their potential and drawbacks are still under investigation.
While single agents BRAF and MEK inhibitors have shown limitations, their combination has been proposed to cause sustained MAPK pathway inhibition. However, studies already predict resistance occurring following this treatment strategy. treatment strategy, and alternative therapies and targets must be available to curb disease progress.
In this study, we explore the intrinsic resistance mechanisms of metastatic melanomas against MEK inhibition by interrogating a panel of genetically diverse human melanoma cell lines. We observed that MEK inhibition (by UO126 and AZD6244) increased the invasion potential of a cohort of human melanoma cell lines in a variety of models, including skin reconstructs. MEK inhibition in this cohort of melanomas is associated with increased RTK activity and the activation of the signal transducers and activators of transcription-3 (STAT3) pathway. We further show that downregulation of STAT3 activity or upstream RTKs prevent the invasive phenotype. Finally, we observed that invasion and STAT3 pathway activation is a hallmark of BRAF-inhibitor-resistant melanoma cell lines.
RESULTS

MEK inhibition causes increased migration/invasion of melanoma cell lines
We investigated the effects of MEK inhibition in multiple melanoma cell lines, using the MEK inhibitors UO126 and AZD6244, in a collagen-embedded spheroid assay that mimics the three-dimensional (3D) skin tissue microenvironment. 24 Following 72 h treatment with UO126 or AZD6244, we observed that 4/20 (20%) metastatic melanoma cell lines tested displayed significantly increased invasion (Figure 1a and b; Supplementary Figure 1A ), while spheroid size was not greatly affected. MEK inhibition, however, reduced invasion and spheroid size in the non-metastatic cell lines WM35 and WM793 (Figure 1c ), in agreement with previous work indicating their sensitivity to MEK inhibitors. 24 The BRAF and NRAS mutation status of each cell line did not predict the increased invasion, and MEK mutations were not identified to contribute to such a phenotype (Table 1) .
We further conducted a transwell migration/invasion assay through a layer of collagen and confirmed the increased migration potential of melanoma cells as single cell entities (Figure 1d and e). Invasion was increased at least threefold for all treated cell lines compared with untreated cells, and was significant for two out of three cell lines using this invasion assay; however, this was likely owing to the small number of invading cells in one cell line. To ascertain that the invasive phenotype was also applicable to a more complex microenvironment, we used a human skin reconstruct model featuring the co-culture of multiple cell types, including keratinocytes and fibroblasts. This skin-like model demonstrated that MEK-inhibitor-treated melanoma cells invade deeper into the dermis than vehicle control-treated cells (Figure 1f, Supplementary Figures 1B and 1C) . Even for metastatic cell lines that are initially invasive, such as 1205Lu, significant differences were observed in UO126-treated skin reconstructs (Figure 1g ). Our data indicate that the MEK-inhibitor-induced invasive phenotype occurs in multiple invasion assays, in the presence of multiple cell types, and in a human skin reconstruct model.
RTKs are activated upon MEK inhibition
The potential of MEK inhibitors to halt invasion and spheroid growth in early-stage melanomas while activating spheroid invasion in some metastatic cell lines allowed us to explore the distinct signaling mechanisms involved in melanoma intrinsic resistance to MEK inhibition. We thus conducted a phosphoantibody array comparing a cell line that is resistant and invades upon MEK inhibition (WM3918) versus a cell line that is sensitive to MEK inhibition (WM793), 28 in the presence or absence of a MEK inhibitor (AZD6244). We found that treatment with the MEK inhibitor for 72 h led to increased phosphorylation of selected RTKs in both tested cell lines (Figure 2a) . However, there were distinct differences between the RTKs activated in the invasive cell line and the MEK-inhibitor-sensitive cell line. Phosphorylation of PDGFRb, fibroblast growth factor receptor, insulin receptor and insulin-like growth factor 1 receptor were selectively increased in WM3918. Interestingly, IGFR and PDGFR have also been associated with resistance to BRAF inhibitors in melanoma. 9, 25 We further confirmed the increased expression of IGFR and PDGFR following UO126 treatment in the invasive melanoma cell lines (WM3918 and 1205Lu) compared with the MEK-sensitive cell line WM793 (Figure 2b ). The erythropoietin-producing hepatocellular kinase A2 was the only phospho-RTK downregulated in the MEK-resistant and invasive cell line, while it was upregulated in the sensitive cell line.
Invasion following MEK inhibition is associated with activation of the Src/FAK/STAT3 signaling axis in 2D and 3D culture While our previous studies indicated the importance of the PI3K/ Akt pathway for melanoma survival following MAPK pathway inhibition, 9, 24 we hypothesized that other pathways are also activated and could contribute to the intrinsic resistance of melanoma cells to MAPK inhibitors. For example, IGF-I/IGF-IR is able to mediate activation of the STAT3 in vitro and in vivo via the Janus kinase (JAK). 29 Also, Src kinase activity can activate STAT3 preassembled with PDGFR receptors, 30 and STAT3 binding to fibroblast growth factor receptor was shown to be activated by receptor amplification. 31 The involvement of the Src/STAT3 axis in mediating growth and survival of melanoma cells was previously demonstrated. 32 We therefore examined the activation of the Src, FAK and STAT3 signaling axis in melanoma cell lines that become invasive following MEK inhibition. Figure 2c (and Supplementary  Figure 2 ) data show that in 2D culture, MEK inhibition can lead to the phosphorylation of Src, FAK and STAT3, while MEK and ERK phosphorylation is downregulated. Given that the invasive phenotype is difficult to observe in 2D culture and signaling in 2D versus 3D cultures may be distinct, we also confirmed STAT3 activation in cell extracts isolated from our 3D collagen-embedded spheroid cultures (Figure 2c , lower panels). We further confirmed increased FAK phosphorylation and STAT3 localization to the nucleus (indicating activation) upon MEK inhibition by immunofluorescent imaging (Figure 2d ). Interestingly, western blot analysis indicates that whereas MEK inhibition upregulates Src/ FAK/STAT3 activity and causes increased invasion in metastasisderived cell lines, MEK inhibition in early-stage melanoma cells (for example, WM793) does not induce Src/FAK/STAT3 activity or invasion (Figure 2e ). These data suggest a potential role for STAT3 in melanoma cells' intrinsic resistance to MEK inhibition.
STAT3 phosphorylation increases in a MEK inhibitor dose-and time-dependent manner There is an inverse correlation between ERK and STAT3 phosphorylation in invasive cell lines (exemplified by WM3918) as the MEK inhibitor UO126 dose increases (Figure 3a) . The MEK inhibitor AZD6244 also displays this correlation (Supplementary Figure 3) . We also noted an increase in STAT3 phosphorylation over time, most notably occurring at 12 h post-compound addition (Figure 3b) . While it was shown previously that cell-tocell adhesion alone can mediate STAT3 phosphorylation, 33 MEK inhibitor addition could potentiate this effect. To explore if increased cadherin engagement could be involved in UO126-mediated STAT3 phosphorylation, especially given the altered cell morphology and increased adhesion seen following compound addition (Figure 3c ), we evaluated levels of E-and N-cadherin following UO126 addition in WM3918 and WM983B cells. We observed an increase in N-cadherin expression in a single cell line (WM983B) while E-cadherin levels remained even (Figure 3d ), suggesting their possible yet incomplete involvement in potentiating STAT3 phosphorylation following MEK inhibition.
Targeting the STAT3 pathway prevents the invasive phenotype induced by MEK inhibition The complex signaling mechanisms found in melanoma indicate that multiple pathways are involved in mediating biological responses to a given inhibitor. To confirm the importance of the STAT3 pathway in mediating resistance to MEK inhibition, we knocked down STAT3 in our MEK-induced invasive melanoma cell lines. Two independent short-hairpin RNAs were transduced via lentiviral infection and each short-hairpin RNA caused a reduction in total STAT3 levels ( Figure 4a ). We selected invasive cell lines and their respective STAT3-knockdown counterparts to grow as spheroids in collagen or expose to a transwell invasion assay. As shown in Figure knockdown in a different cell line, while less efficient, also reduced invasion as assessed using a transwell invasion assay (Supplementary Figure 4) . We next examined whether we could offset the MEK-inhibitor-induced invasive phenotype by combining a MEK inhibitor with compounds targeting multiple RTKs and Src family kinases (dasatinib), or STAT3 (CPA-7). 34 Using a fluorescent stain for live and dead cells, we detected increased intra-spheroid cell death and reduced invasion in the combination treatments compared with single-agent MEK treatment (Figure 4b ). Using a transwell invasion assay, we observed that both dasatinib and CPA-7 had anti-invasive properties and prevented MEK-inhibitor-induced invasion; CPA-7 was more potent than dasatinib in halting this invasion (Figure 4c ).
STAT3 phosphorylation is increased in BRAF-resistant melanoma cells Given the current use of BRAF inhibitors for the treatment of BRAF V600E mutant melanomas, we explored whether MAPK inhibition using a BRAF inhibitor instead of a MEK inhibitor could also cause increased invasion and STAT3 phosphorylation in metastatic melanoma cell lines. The addition of the BRAF inhibitor SB590885 (SB-885) significantly increased the invasion of each two BRAFV600E mutant cell lines, but only transiently (following a 20 h treatment) (Figure 5a ), before cell death was observed (data not shown). While BRAFV600E cell lines are sensitive to the addition of a BRAF inhibitor, they still upregulate the STAT3 pathway, most notably in their counterparts that were rendered BRAF-inhibitor-resistant (Figure 5b) . 9 BRAF-inhibitor-resistant cell lines also formed more invasive spheroids (without MEK inhibition); however, they were sensitive to the addition of the STAT3 inhibitor CPA-7 (alone and in combination with a BRAF inhibitor), which caused reduced spheroid size in one cell line and abrogated the invasive phenotype ( Figure 5c ).
Taken together, our data suggest that in a cohort of resistant melanoma cells, BRAF or MEK inhibitors cause the upregulation of RTKs and engagement of downstream signaling pathways such as the Src/FAK/STAT3 network, which contribute to an invasive and more aggressive phenotype.
DISCUSSION
In this study, we explored novel compensatory mechanisms employed by melanoma cells in order to resist MAPK inhibition, with an emphasis on MEK inhibition. While most preclinical studies focused on MEK inhibition have been conducted in the twodimensional culture setting, which limits certain observations, here we noticed that a cohort of human melanoma cell lines grown as 3D spheroids embedded in collagen displayed an enhanced invasive phenotype. MEK-inhibitor-induced invasion was validated using other invasion models and was shown for multiple cell lines. Our findings were initially generated using the MEK inhibitor UO126; however, this compound is not clinically applicable, thus we confirmed our observations with AZD6244, which showed similar results. Invasion did not correlate with the mutation status of BRAF or MEK, indicating that a more extensive knowledge of the genetic or signaling cellular background is required in order to predict which cell lines will respond adversely. Indeed, the invasion observed occurred despite the persistent inhibition of ERK phosphorylation, even following 72 h treatment with UO126 or AZD6244, suggesting the important role of other pathways to compensate and mediate this cellular response. Interestingly, others have previously shown that MAPK inhibition can induce a more aggressive phenotype or cell migration in a subgroup of cell lines when plated on a basement membrane-like matrix. 8, 35 Our results are in accordance with these findings, extend the observations to more complex 3D culture models and add MEK inhibitors to the list of compounds that need to be carefully characterized and monitored in certain patients. Indeed, as reported for VEGF-R inhibitors, there is potential to increase the metastatic potential of tumor cells by using small molecule inhibitors in the wrong cellular MEK/STAT3 signaling in melanoma A Vultur et al background. 36, 37 While for VEGF-R-mediated increased metastasis, hypoxia was suggested as a possible facilitator of invasion, our invasion observations using the 3D spheroid model with MEK inhibition did not change even following 5 days of growth in 1% O 2 hypoxic conditions (data not shown). Instead, our data support the hypothesis that a re-wiring of pathways following MAPK small molecule inhibitor addition and engagement of counteracting networks cause an invasive phenotype. (c) Graph depicting the invasion of melanoma cells using a transwell invasion assay following treatment with UO126 (MEK inhibitor, 10 mM), dasatinib (SRC/RTK inhibitor, 1 mM), and CPA-7 (STAT3 inhibitor, 10 mM) or combinations thereof. The analysis of variance was significant for drug treatment but effects were different for the two cell lines. Specific comparisons show significant differences (*) between UO126 and UO126 þ CPA-7-treated cells for both cell lines and a significant difference between UO126 and UO126 þ dasatinib for WM3918 only. We have previously shown the involvement of the IGFR/PI3K pathway along with reactivation of MAPK signaling in counteracting BRAF inhibition. 38 Our phospho-RTK array and western blot results following MEK inhibitor addition also show the involvement of insulin-like growth factor 1 receptor. While we do not discount that IGFR/PI3K signaling is involved in the intrinsic resistance of melanoma to MEK inhibition, as it is for BRAF inhibition, here we focused on identifying novel signaling networks that could contribute to resistance and invasion following MAPK pathway inhibition. IGFR, PDGFR and FGF-R signaling has been previously shown to activate the STAT3 pathway; [29] [30] [31] additionally, studies carried out in STAT3 null cells demonstrated that STAT3 represents an essential effector pathway of Rho GTPases in regulating multiple cellular functions, including actin cytoskeleton reorganization, gene activation and cell migration.
39 Thus, we hypothesized and then confirmed that STAT3 is activated following MEK inhibitor addition (in both 2D and 3D melanoma cultures).
The regulation of STAT3 activity is complex and is the point of convergence for many tyrosine kinase signals. 32 In addition to growth factors and cytokine stimulation, cell-to-cell adhesion and cadherin engagement were also shown to promote STAT3 activation and support cell survival. 33, 40 We observed that confluence in our melanoma cells increases STAT3 phosphorylation, but the signal is potentiated in the presence of a MEK inhibitor. This observation can be explained by previous findings demonstrating that cadherins and integrins associate directly with RTKs to upregulate a number of pathways and support cellular responses, such as invasion, proliferation and survival (reviewed in Christofori 41 ). Thus, both the engagement of cell adhesion molecules and the contribution of multiple RTKs activity could contribute to STAT3 activation in aggressive melanoma cells. Indeed, examination of E-and N-cadherin levels following MEK inhibitor addition showed that higher N-cadherin levels were induced. This was observed in only one treated cell line, suggesting a partial and cell-dependent involvement of cadherins in STAT3 activation. Crosstalk between the MAPK and STAT3 pathways was previously described at the Ser727 site on STAT3, a phosphorylation site that has its own role and regulation of STAT3 activity. 42, 43 MEK inhibition in both our sensitive and resistant cell lines showed a decrease in phospho-STAT3 Ser727 levels; therefore, the regulation of this site alone does not explain the differential response of our melanoma cells to MEK inhibition (data not show).
While the mechanism of STAT3 activation following MEK inhibition may be complex, we sought to show its role in mediating resistance and invasion in our melanoma models. Indeed, our STAT3-knockdown studies indicate that downregulated STAT3 prevents MEK-induced invasion. Furthermore, a tool compound inhibiting STAT3 (CPA-7) also showed that targeting this pathway prevents invasion in different assays and displays cytotoxic effects in 3D melanoma spheroids. Small molecule inhibitors of STAT3 are not yet approved for therapeutic use, but clinical trials are ongoing to identify effective drugs (for example, OPB-31121, Otsuka Pharma, Rockville, MD, USA). However, compounds targeting upstream effectors of the STAT3 pathway, such as RTKs, Src and JAKs, are available and have already been assessed in the clinic. Our study shows that targeting RTKs with dasatinib does not cause extensive spheroid cell death compared with targeting STAT3 directly, in agreement with previous studies. 44 However, higher drug concentrations may be warranted to achieve cell death when a MEK inhibitor is present as the drug target activities, namely that of the RTKs and Src, are upregulated. In accordance with our findings, recent MEK and SRC inhibitor combinations have shown anti-melanoma activity. 45 Also encouragingly, inhibition of the JAK/STAT3 signaling pathway was shown to impede the migratory and invasive potential of human glioblastoma cells and the effects were observed in both PTENexpressing and PTEN-deficient cells. 46 The combination of MEK inhibitors and effectors of the STAT3 pathway may therefore be useful in curbing melanoma progression and increase patient survival.
Finally, we extended our observations of an increasingly activated STAT3 pathway in BRAF-resistant melanoma cell lines, which are also more invasive compared with their parental counterparts. These observations indicate that SRC, JAK and STAT3 inhibitors could also be useful for BRAF-inhibitor-resistant melanoma cases.
In sum, our studies indicate that, despite harboring high MAPK pathway activity, not all melanomas respond favorably to inhibition of the pathway and can engage an intrinsically resistant response with potential adverse effects such as induced invasion. We identify STAT3 as a pathway upregulated upon MEK inhibition in a cohort of aggressive melanoma cell lines, and in cell lines rendered resistant to BRAF inhibition. Our study also highlights the usefulness of 3D culture models to further characterize compounds and their potential adverse effects. A future challenge will be to identify which patients will most benefit from a MEK, BRAF and SRC/JAK/STAT3 inhibition combination. Such a treatment strategy may be useful for all patients, or could provide a novel option to patients displaying intrinsic or acquired resistance to MAPK pathway inhibitors. In addition, given the role of STAT3 in evading the immune response, it would be interesting to explore the correlation between STAT3 activity and response to immunotherapies.
MATERIALS AND METHODS
Cell culture and reagents Human melanoma cell lines have been previously described. 47, 48 All cell lines were cultured in Dulbecco's modified Eagle's medium supplemented with 5% fetal bovine serum and grown at 37 1C in 5% CO 2 . The consistency of cellular genotypes and cell line identities were confirmed by DNA fingerprinting using Coriell's microsatellite kit (Camden, NJ, USA). UO126 was purchased from Promega (Madison, WI, USA); AZD6244 and dasatinib were purchased from Chemietek (Indiannapolis, IN, USA); PLX4720 was provided by Plexxikon/Roche (Berkeley, CA, USA), CPA-7 was a gift from Dr L Raptis (Queen's University, Canada). All compounds were stored in dimethyl sulfoxide as 10 mM stocks and stored at À 20 1C. Lentiviral short-hairpin RNAs (TRCN0000020842 and TRCN0000020840 for STAT3) were in the pLKO.1puro vector and were obtained from Sigma (St Louis, MO, USA). . BRAF: Genomic DNA from samples were analyzed for mutations in BRAF by the nucleotide extension assay using the iPlex platform (Sequenom Inc., San Diego, CA, USA). [49] [50] [51] [52] 3D spheroid assay Melanoma spheroids were prepared 53 and stained 54 as previously described. Collagen-embedded spheroids were treated with inhibitors for 72 h before staining or imaging. Spheroids were imaged using a TE2000 Nikon inverted fluorescence microscope (Melville, NY, USA).
Invasion assay Transwell invasion chambers (Becton Dickinson, Franklin Lakes, NJ, USA), 24-well format, were used according to the manufacturer's instructions and 50 ml of collagen mix (as mentioned above) were used to coat the membrane before use. Briefly, cells were suspended in 100 ml serum-free medium before being loaded into an upper invasion chamber. Cells were allowed to adhere for 4 h with the upper chamber sitting in a well containing 750 ml of freshly collected conditioned medium from each respective cell line grown for 72 h. Inhibitors or the vehicle control dimethyl sulfoxide were then added in 100 ml serum-free medium for a final concentration as indicated, and the cells were allowed to migrate for 72 h toward conditioned media. Before imaging, non-invasive cells were removed from the upper chamber and the remaining invasive cells were stained with 4 0 6-diamidino-2-phenylindole. Fluorescent staining was examined using a Nikon TE2000 inverted microscope.
Western blots and RTK array analyses Proteins were extracted as previously described 55 and 50 mg of cell extract were resolved on a 10% polyacrylamide-SDS gel before being transferred onto a polyvinylidene membrane (Millipore, Billerica, MA, USA). Membranes were handled and imaged as previously described, 56 or they were analyzed using the Odyssey Infrared Imaging System (Li-Cor, Lincoln, NE, USA). All primary antibodies were from Cell Signaling Technologies (Beverly, MA, USA). The secondary antibodies IRDye 700 and IRDye 800 were from Li-Cor. To identify the relative levels of phosphorylation of RTKs, we used a human phospho-RTK array kit (ARY001; R&D Systems, Minneapolis, MN, USA), according to manufacturer instructions.
Immunofluorescence Cells were grown on a glass coverslip and were treated with dimethyl sulfoxide or MEK inhibitor for 72 h before fixation and imaging as previously described. 55 Antibodies used were anti-FAK pY576/577, anti-pSTAT3Y705 (Cell Signaling Technologies), AlexaFluor488 Phalloidin and anti-rabbit AlexaFluor488 secondary antibodies (Life Technologies, Carlsbad, CA, USA). S100 (DAKO, Carpinteria, CA, USA) and isotype-matched IgG control antibodies were used to stain fixed skin reconstruct samples.
Human skin reconstructs Human skin reconstructs were generated as described previously. 57 Briefly, inserts of tissue culture trays (Organogenesis, Canton, MA, USA) were coated with 1 ml bovine collagen I mixture (Organogenesis) and layered with 3 ml collagen I mixture containing 7.5 Â 10 4 fibroblasts. After 4 to 7 days of incubation at 37 1C, melanoma cells were mixed with keratinocytes and seeded on top of the dermal reconstructs at a ratio of 1:5 (melanoma cells to keratinocytes). Cells were cultured in skin reconstruct media (Supplementary Materials and methods), then raised to the air-liquid interface on day 5, via feeding from below with medium. Two weeks later, skin reconstructs were harvested for imaging or fixed in 10% neutral buffered formalin for 4-6 h before being processed by routine histological methods. The exposure of skin reconstructs to inhibitors involved the pretreatment of melanoma cells (with vehicle control or 10 mM of MEK inhibitor) before mixing with the keratinocytes, then the addition of compound (same concentration) to the feeding media in the last 72 h of skin reconstruct growth. Two-photon microscopy imaging Deep tissue imaging was performed using a Prairie Ultima II 2-photon microscope (Prairie Technologies Inc., Middleton, WI, USA). The system incorporates a fixed-stage upright Olympus BX61WI microscope (Center Valley, PA, USA), a Chameleon XR femtosecond pulsed Ti:Sapphire laser (Coherent Laser Group, Santa Clara, CA, USA) with excitation ranging from 710-980 nm, and a 4-channel, filter-based detection system. Unfixed tissue samples were directly imaged with a Â 40 PlanFl/IR water immersion lens to a standardized depth of 200 mm. Excitation at 910 nm provided signal from the green fluorescent protein-labeled melanoma cells and also provided a second harmonic signal to visualize the upper collagen layer. Stacks of 100 slices were generated in two channels, and 3D reconstruction and analysis was accomplished using ImagePro Plus 3D software (Media Cybernetics, Silver Spring, MD, USA).
Statistical analysis
The two-way analysis of variance was used to test for treatment effects on invasion controlling for cell line after taking the natural logarithm of invasion. When there was a significant interaction, comparisons were done for each cell line. t-tests using Satterwaithe's method, when variances were unequal, were used to test for cell line-specific treatment effects on distance traveled in the skin reconstruct experiments. Tukey's procedure was used to evaluate pairwise differences when an analysis of variance was significant. Error bars represent s.e.
